ArticleJACS Au2025
Asymmetric Catalytic [3 + 3] Annulations of Unmodified Morita-Baylis-Hillman Alcohols to Construct Diverse Heterobicyclic [4.3.0] Skeletons.
Article in JACS Au, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Due to the high C-OH bond dissociation energy and unpredictable site selectivity, the direct application of unmodified cyclic MBH alcohols presents significant challenges. Herein, we described a series of highly enantioselective β,β'-site-selective annulations of unmodified cyclic MBH alcohols, which provides a strategy for the asymmetric construction of structurally diverse chiral heterobicyclic [4.3.0] skeletons. Azabicyclic, oxobicyclic, and thiabicyclic [4.3.0] skeletons could be synthesized with excellent stereoselectivities through this general platform. Catalyst rather than substrate-controlled feature renders the reaction minimal sensitivity to substrate properties. Furthermore, the synthetic potential of this method was underscored by facile access to various pharmaceutically active analogues. This synthetic strategy would accelerate access to accomplish diverse transformations of MBH adducts and advance the frontiers of chiral heterocyclic synthesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.